CU20200057A7 - COMPOSICIONES VACUNALES CONTRA EL VIRUS SARS-CoV-2 BASADAS EN UN DÍMERO DEL DOMINIO DE UNIÓN AL RECEPTOR Y LA VESÍCULA DE MEMBRANA EXTERNA DEL MENINGOCOCO B - Google Patents

COMPOSICIONES VACUNALES CONTRA EL VIRUS SARS-CoV-2 BASADAS EN UN DÍMERO DEL DOMINIO DE UNIÓN AL RECEPTOR Y LA VESÍCULA DE MEMBRANA EXTERNA DEL MENINGOCOCO B

Info

Publication number
CU20200057A7
CU20200057A7 CU2020000057A CU20200057A CU20200057A7 CU 20200057 A7 CU20200057 A7 CU 20200057A7 CU 2020000057 A CU2020000057 A CU 2020000057A CU 20200057 A CU20200057 A CU 20200057A CU 20200057 A7 CU20200057 A7 CU 20200057A7
Authority
CU
Cuba
Prior art keywords
cov
sars
vaccine compositions
outer membrane
receptor
Prior art date
Application number
CU2020000057A
Other languages
English (en)
Other versions
CU24711B1 (es
Inventor
Ayo Tammy Boggiano
Cuervo Mario Landys Chovel
Ruiz Yanet Climent
Castillo Sonsire Fernández
Rivera Dagmar García
Rodríguez Humberto González
Chen Guangwu
Magraz Eduardo Ojito
Hernández Reynaldo Oliva
Nicado Rocmira Pérez
González Ubel Jesús Ramírez
Noda Laura Marta Rodríguez
Ramírez Belinda Sánchez
Balbín Yury Valdés
Bencomo Vicente Guillermo Verez
Original Assignee
Ct Inmunologia Molecular
Inst Finlay De Vacunas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to MX2023002081A priority Critical patent/MX2023002081A/es
Priority to JP2023512368A priority patent/JP2023547758A/ja
Priority to US18/021,731 priority patent/US20230330213A1/en
Priority to KR1020237008763A priority patent/KR20230098136A/ko
Priority to PCT/CU2021/050007 priority patent/WO2022037727A1/es
Priority to AU2021326938A priority patent/AU2021326938A1/en
Priority to EP21786322.4A priority patent/EP4201423A1/en
Priority to CU2020000057A priority patent/CU24711B1/es
Application filed by Ct Inmunologia Molecular, Inst Finlay De Vacunas filed Critical Ct Inmunologia Molecular
Priority to CA3192260A priority patent/CA3192260A1/en
Priority to CN202180051119.XA priority patent/CN116635065A/zh
Priority to BR112023002872A priority patent/BR112023002872A2/pt
Publication of CU20200057A7 publication Critical patent/CU20200057A7/es
Priority to CL2023000508A priority patent/CL2023000508A1/es
Publication of CU24711B1 publication Critical patent/CU24711B1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/165—Coronaviridae, e.g. avian infectious bronchitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55588—Adjuvants of undefined constitution
    • A61K2039/55594—Adjuvants of undefined constitution from bacteria
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

<p>La presente invención se relaciona con la biotecnología, específicamente con el campo de la salud humana. Proporciona composiciones vacunales que inducen una respuesta inmune neutralizante contra el SARS-CoV-2. Estas composiciones vacunales comprenden como antígeno una porción de la proteína de unión al receptor del SARS-CoV-2 y vesículas derivadas de proteínas de la membrana externa de <em>Neisseria meningitidis</em> grupo B como inmunopotenciador y adicionalmente un adyuvante. Las composiciones vacunales que se describen en la presente invención son útiles en la prevención de la infección por el virus SARS-CoV-2.</p>
CU2020000057A 2020-08-20 2021-08-05 Composiciones vacunales contra el virus sars-cov-2 basadas en un dímero del dominio de unión al receptor y la vesícula de membrana externa del meningococo b CU24711B1 (es)

Priority Applications (12)

Application Number Priority Date Filing Date Title
EP21786322.4A EP4201423A1 (en) 2020-08-20 2021-08-05 Compositions of sars-cov-2 vaccines based on the receptor binding domain, expressed as a dimer, and the outer membrane vesicle of meningococcal group b bacteria
US18/021,731 US20230330213A1 (en) 2020-08-20 2021-08-05 Compositions of sars-cov-2 vaccines based on the receptor binding domain, expressed as a dimer, and the outer membrane vesicle of meningococcal group b bacteria
KR1020237008763A KR20230098136A (ko) 2020-08-20 2021-08-05 이량체로 발현된 수용체 결합 도메인 및 수막구균 b 그룹 세균의 외막 소낭을 기반으로 하는 sars-cov-2 백신 조성물
PCT/CU2021/050007 WO2022037727A1 (es) 2020-08-20 2021-08-05 Composiciones vacunales contra el virus sars-cov-2 basadas en un dímero del dominio de unión al receptor y la vesícula de membrana externa del meningococo b
AU2021326938A AU2021326938A1 (en) 2020-08-20 2021-08-05 Compositions of sars-cov-2 vaccines based on the receptor binding domain, expressed as a dimer, and the outer membrane vesicle of meningococcal group b bacteria
MX2023002081A MX2023002081A (es) 2020-08-20 2021-08-05 Composiciones vacunales contra el virus sars-cov-2 basadas en un dimero del dominio de union al receptor y la vesicula de membrana externa del meningococo b.
CN202180051119.XA CN116635065A (zh) 2020-08-20 2021-08-05 基于受体结合结构域的二聚体和B群脑膜炎球菌的外膜囊泡的针对SARS-CoV-2病毒的疫苗组合物
CU2020000057A CU24711B1 (es) 2020-08-20 2021-08-05 Composiciones vacunales contra el virus sars-cov-2 basadas en un dímero del dominio de unión al receptor y la vesícula de membrana externa del meningococo b
CA3192260A CA3192260A1 (en) 2020-08-20 2021-08-05 Compositions of sars-cov-2 vaccines based on the receptor binding domain, expressed as a dimer, and the outer membrane vesicle of meningococcal group b bacteria
JP2023512368A JP2023547758A (ja) 2020-08-20 2021-08-05 二量体として発現される受容体結合ドメインに基づくＳＡＲＳ－ＣｏＶ－２ワクチン及び髄膜炎菌Ｂ群細菌の外膜小胞の組成物
BR112023002872A BR112023002872A2 (pt) 2020-08-20 2021-08-05 Composição de vacina que induz uma resposta imune contra o vírus sars-cov-2, procedimento para obter as omvs, e, uso da composição de vacina
CL2023000508A CL2023000508A1 (es) 2020-08-20 2023-02-20 Composiciones vacunales contra el virus sars-cov-2 basadas en un dímero del dominio de unión

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/CU2021/050007 WO2022037727A1 (es) 2020-08-20 2021-08-05 Composiciones vacunales contra el virus sars-cov-2 basadas en un dímero del dominio de unión al receptor y la vesícula de membrana externa del meningococo b
CU2020000057A CU24711B1 (es) 2020-08-20 2021-08-05 Composiciones vacunales contra el virus sars-cov-2 basadas en un dímero del dominio de unión al receptor y la vesícula de membrana externa del meningococo b

Publications (2)

Publication Number Publication Date
CU20200057A7 true CU20200057A7 (es) 2022-04-07
CU24711B1 CU24711B1 (es) 2024-07-10

Family

ID=78077964

Family Applications (1)

Application Number Title Priority Date Filing Date
CU2020000057A CU24711B1 (es) 2020-08-20 2021-08-05 Composiciones vacunales contra el virus sars-cov-2 basadas en un dímero del dominio de unión al receptor y la vesícula de membrana externa del meningococo b

Country Status (12)

Country Link
US (1) US20230330213A1 (es)
EP (1) EP4201423A1 (es)
JP (1) JP2023547758A (es)
KR (1) KR20230098136A (es)
CN (1) CN116635065A (es)
AU (1) AU2021326938A1 (es)
BR (1) BR112023002872A2 (es)
CA (1) CA3192260A1 (es)
CL (1) CL2023000508A1 (es)
CU (1) CU24711B1 (es)
MX (1) MX2023002081A (es)
WO (1) WO2022037727A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117883562A (zh) * 2023-12-22 2024-04-16 苏州大学 一种细菌外膜囊泡为模板的氢氧化铝纳米颗粒及其制备方法和应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU21888A1 (es) 1987-07-30 1997-01-06 Inst Finlay Método para la obtención de una vacuna de amplio espectro protector contra la nisseria meningitidis del grupo b y la vacuna resultante
GB0316560D0 (en) * 2003-07-15 2003-08-20 Chiron Srl Vesicle filtration
GB0416120D0 (en) 2004-07-19 2004-08-18 Health Prot Agency Stable compositions containing OMV's
CN111983226A (zh) * 2020-03-25 2020-11-24 新加坡国立大学 SARSr-CoV抗体的检测

Also Published As

Publication number Publication date
CU24711B1 (es) 2024-07-10
MX2023002081A (es) 2023-05-19
CL2023000508A1 (es) 2023-10-06
CN116635065A (zh) 2023-08-22
JP2023547758A (ja) 2023-11-14
AU2021326938A1 (en) 2023-05-04
BR112023002872A2 (pt) 2023-03-14
EP4201423A1 (en) 2023-06-28
US20230330213A1 (en) 2023-10-19
WO2022037727A1 (es) 2022-02-24
CA3192260A1 (en) 2022-02-24
KR20230098136A (ko) 2023-07-03

Similar Documents

Publication Publication Date Title
Karch et al. Vaccination with self-adjuvanted protein nanoparticles provides protection against lethal influenza challenge
EA200900024A1 (ru) Противогриппозная вакцина
EA201391515A1 (ru) Инактивированная вакцина вируса денге
EA200701786A1 (ru) Поливалентная противогриппозная иммуногенная композиция
MX2010012999A (es) Vacuna de vesícula de membrana externa nativa multivalente del meningococo, método para su fabricación y uso.
BR112012022800A2 (pt) composição imunogênica ou vacina, cepa bacteriana gram-negativa geneticamente engenheirada, métodos para o tratamento ou prevenção de infecção ou doença, para produzir uma composição imunogênica ou uma vacina, e para preparar uma imunoglobulina, preparação da imunoglobulina, e, preparação farmacêutica
CY1111056T1 (el) Εμβολιο κυστιδιου εξωτερικης μεμβρανης (omv) που περιλαμβανει πρωτεϊνες εξωτερικης μεμβρανης απο ν. meningitidis οροομαδας β
BR112015002131A2 (pt) vacina de vírus sincicial respiratório (rsv) de vírus vaccínia ancara modificado recombinante
PH12021550479A1 (en) Dengue vaccine unit dose and administration thereof
UY33297A (es) Composiciones farmaceuticas que comprenden un polipéptido que comprende al menos un motivo cxxc y antígenos heterólogos y usos de las mismas
EA201391200A1 (ru) Способы и композиции для вакцинации от staphylococcus aureus
AR059648A1 (es) Antigenos vacunales quimericos contra el virus de la peste porcina clasica
CO6460752A2 (es) Respuesta inmunitaria reforzada en especies aviares
MX383416B (es) Nueva vacuna contra la influenza porcina.
WO2007098718A8 (es) Antígenos vacunales quiméricos contra el virus de la influenza aviar
BRPI0918806A2 (pt) composição compreendendo quitosana para administração ocular de vaninas em aves
CL2023000508A1 (es) Composiciones vacunales contra el virus sars-cov-2 basadas en un dímero del dominio de unión
BR112023018397A2 (pt) Composições de proteína de fusão imunomoduladora biomodificada
RU2010120324A (ru) Вакцина против вируса синего языка и иммуногенные композиции, способы их применения и способы их получения
AU2013370982C1 (en) Immunogenic composition comprising mycoplasma antigens
BR112022020298A2 (pt) Vacinas, adjuvantes e métodos para gerar uma resposta imune
CL2023001142A1 (es) Composiciones y métodos para la vacunación contra neisseria gonorrhoeae
BR112013013016A2 (pt) modulação de imunogenicidade de antígeno pela eliminação de epítopos reconhecidos pelas células nkt14
EA202190914A1 (ru) Иммуногенные композиции
RU2008144180A (ru) Вакцина против микоплазмы и prrsv